NEW YORK — Volpara Health Technologies said on Wednesday that its Volpara Solutions subsidiary has signed an agreement to link its cancer screening and practice management platform with Ambry Genetics' program for identifying high-risk breast cancer patients.
Under the terms of the deal, Volpara's Aspen Breast software for medical practice management will include an online ordering process for Ambry's genetic tests. Meanwhile, Volpara's Density software for assessing volumetric breast density will be included in Ambry's Comprehensive, Assessment, Risk, and Education (CARE) program, which uses risk assessment models and genetic testing to identify high-risk women and guide future screening and treatment decisions.
Additional terms were not disclosed.
About a year ago, Wellington, New Zealand-based Volpara Health Solutions acquired Lynnwood, Washington-based Medical Reporting Systems, which developed Aspen Breast. Aliso Viejo, California-based Ambry is a unit of Japan's Konica Minolta.